Clinical Trial Update: Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis [Phase 1]

View source ↗

Summary

A Phase 1 trial investigating intrathecal administration of autologous mesenchymal stem cell-derived neural progenitors (MSC-NP) for multiple sclerosis has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• MSC-NP (autologous mesenchymal stem cell-derived neural progenitors)

Snippet

Sponsor: Tisch Multiple Sclerosis Research Center of New York | Conditions: Multiple Sclerosis | Phase 1 | Status: COMPLETED